BTC Capital Management Inc. Acquires 557 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

BTC Capital Management Inc. grew its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.3% during the fourth quarter, HoldingsChannel.com reports. The fund owned 11,030 shares of the pharmaceutical company’s stock after acquiring an additional 557 shares during the quarter. BTC Capital Management Inc.’s holdings in Vertex Pharmaceuticals were worth $4,430,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Mutual Advisors LLC boosted its holdings in shares of Vertex Pharmaceuticals by 0.6% in the 3rd quarter. Mutual Advisors LLC now owns 3,710 shares of the pharmaceutical company’s stock worth $1,751,000 after purchasing an additional 21 shares during the period. Daymark Wealth Partners LLC lifted its stake in shares of Vertex Pharmaceuticals by 2.8% during the 3rd quarter. Daymark Wealth Partners LLC now owns 804 shares of the pharmaceutical company’s stock worth $374,000 after acquiring an additional 22 shares during the last quarter. Grove Bank & Trust boosted its stake in shares of Vertex Pharmaceuticals by 5.7% during the third quarter. Grove Bank & Trust now owns 410 shares of the pharmaceutical company’s stock valued at $191,000 after purchasing an additional 22 shares during the period. Outlook Wealth Advisors LLC grew its stake in Vertex Pharmaceuticals by 2.8% in the 3rd quarter. Outlook Wealth Advisors LLC now owns 892 shares of the pharmaceutical company’s stock worth $415,000 after acquiring an additional 24 shares in the last quarter. Finally, Dunhill Financial LLC increased its holdings in Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 24 shares during the period. Institutional investors own 90.96% of the company’s stock.

Analyst Upgrades and Downgrades

VRTX has been the subject of a number of recent research reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $480.00 price objective on shares of Vertex Pharmaceuticals in a research note on Friday, January 24th. Truist Financial cut their price target on shares of Vertex Pharmaceuticals from $550.00 to $460.00 and set a “buy” rating on the stock in a report on Monday, December 23rd. Morgan Stanley raised their price target on Vertex Pharmaceuticals from $473.00 to $476.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Raymond James reissued a “market perform” rating on shares of Vertex Pharmaceuticals in a report on Thursday, October 10th. Finally, HC Wainwright raised their price target on shares of Vertex Pharmaceuticals from $535.00 to $550.00 and gave the stock a “buy” rating in a research report on Friday. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $495.36.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ VRTX opened at $438.40 on Friday. The firm has a market cap of $112.90 billion, a P/E ratio of -220.30, a PEG ratio of 2.29 and a beta of 0.40. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88. The stock has a fifty day moving average price of $434.34 and a two-hundred day moving average price of $463.31. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating the consensus estimate of $3.61 by $0.77. The company had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter last year, the company posted $3.67 earnings per share. Research analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.93 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.